Molecular and immunophenotypic predictors of response to azacitidine (aza) as frontline therapy for acute myeloid leukemia (AML).

被引：0
|
作者：
Zimmerman, Michael Keith Alister
Grunwald, Michael Richard
Symanowski, James Thomas
Gerber, Jonathan Michael
机构：
[1] Levine Canc Inst, Charlotte, NC USA
[2] Levine Canc Inst, Carolinas HealthCare Syst, Charlotte, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7024
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML)
    Tabah, Ashley
    Huggar, David
    Wang, Si-Tien
    Johnson, Scott J.
    Copher, Ronda
    O'Connell, Thomas
    Leblanc, Thomas W.
    BLOOD, 2020, 136
  • [2] Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia (AML)
    Risueno, Alberto
    See, Wendy L.
    DiNardo, Courtney D.
    Doehner, Hartmut
    Stein, Eytan
    Fathi, Amir T.
    Vyas, Paresh
    Quek, Lynn
    Prebet, Thomas
    Gandhi, Anita K.
    Hasan, Maroof
    BLOOD, 2022, 140
  • [3] Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML
    Daver, Naval
    Garcia-Manero, Guillermo
    Basu, Sreyashi
    Cortes, Jorge E.
    Ravandi, Farhad
    Jabbour, Elias J.
    Assi, Rita
    Brandt, Mark
    Pierce, Sherry
    Gordon, Tauna
    Pemmaraju, Naveen
    Andreeff, Michael
    Ning, Jing
    Kornblau, Steven
    Kadia, Tapan
    Flores, Wilmer
    Matthews, Jairo
    DiNardo, Courtney D.
    Borthakur, Gautam
    Konopleva, Marina
    Allison, James
    Sharma, Padmanee
    Kantarjian, Hagop M.
    BLOOD, 2017, 130
  • [4] Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML)
    Daver, Naval
    Garcia-Manero, Guillermo
    Basu, Sreyashi
    Cortes, Jorge
    Ravandi, Farhad
    Jabbour, Elias
    Assi, Rita
    Brandt, Mark
    Pierce, Sherry
    Gordon, Tauna
    Pemmaraju, Naveen
    Andreeff, Michael
    Ning, Jing
    Komblau, Steven
    Kadia, Tapan
    Flores, Wilmer
    Matthews, Jairo
    Dinardo, Courtney
    Konopleva, Marina
    Allison, James
    Sharma, Padmanee
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S9 - S9
  • [5] Frontline Azacitidine As a Bridge to Allogeneic Transplantation in Acute Myeloid Leukemia
    Grunwald, Michael Richard
    Zimmerman, Michael Keith Allister
    Boselli, Danielle
    Bohannon, Lauren M.
    Robinson, Myra M.
    Peters, Daniel T.
    Ai, Jing
    Knight, Thomas G.
    Trivedi, Jigar
    Plesca, Dragos
    Symanowski, James T.
    Copelan, Edward A.
    Gerber, Jonathan M.
    BLOOD, 2017, 130
  • [6] Phase 2 study of azacitidine (AZA) and venetoclax (VEN) as maintenance therapy for acute myeloid leukemia (AML) patients in remission.
    Bazinet, Alexandre
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Yilmaz, Musa
    Bose, Prithviraj
    Jabbour, Elias
    Valero, Yesid Alvarado
    Chien, Kelly Sharon
    Pemmaraju, Naveen
    Takahashi, Koichi
    Short, Nicholas James
    Daver, Naval Guastad
    Issa, Ghayas C.
    Jain, Nitin
    Bull-Linderman, Debra
    Dinardo, Courtney Denton
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Ravandi, Farhad
    Kadia, Tapan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19018 - E19018
  • [7] Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).
    Dinardo, Courtney Denton
    Stein, Anthony Selwyn
    Stein, Eytan M.
    Fathi, Amir Tahmasb
    Schuh, Andre C.
    Fernandez, Pau Montesinos
    Odenike, Olatoyosi
    Kantarjian, Hagop M.
    Stone, Richard M.
    Collins, Robert
    Martinelli, Giovanni
    Arnan, Montserrat
    Wu, Bin
    Koralek, Daniel O.
    Van Oostendorp, Jason
    Gong, Jing
    MacBeth, Kyle J.
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)
    Gore, Steven D.
    Cogle, Christopher R.
    Skikne, Barry
    Laille, Eric
    Shi, Tao
    MacBeth, Kyle J.
    Giordano, Heidi
    Garcia-Manero, Guillermo
    BLOOD, 2011, 118 (21) : 671 - 672
  • [9] Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
    Stahl, Maximilian
    Derkach, Andriy
    Farnoud, Noushin
    Bewersdorf, Jan Philipp
    Robinson, Troy
    Famulare, Christopher
    Cho, Christina
    Devlin, Sean
    Menghrajani, Kamal
    Patel, Minal A.
    Cai, Sheng F.
    Miles, Linde A.
    Bowman, Robert L.
    Geyer, Mark B.
    Dunbar, Andrew
    Epstein-Peterson, Zachary D.
    McGovern, Erin
    Schulman, Jessica
    Glass, Jacob L.
    Taylor, Justin
    Viny, Aaron D.
    Stein, Eytan M.
    Getta, Bartlomiej
    Arcila, Maria E.
    Gao, Qi
    Barker, Juliet
    Shaffer, Brian C.
    Papadopoulos, Esperanza B.
    Gyurkocza, Boglarka
    Perales, Miguel-Angel
    Abdel-Wahab, Omar
    Levine, Ross L.
    Giralt, Sergio A.
    Zhang, Yanming
    Xiao, Wenbin
    Pai, Nidhi
    Papaemmanuil, Elli
    Tallman, Martin S.
    Roshal, Mikhail
    Goldberg, Aaron D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (01) : 79 - 89
  • [10] Immunophenotypic identification of acute myeloid leukemia (AML) with monocytic differentiation
    Xu, Y
    McKenna, RW
    Wilson, KS
    Karandikar, NJ
    Schultz, RA
    Kroft, SH
    MODERN PATHOLOGY, 2005, 18 : 258A - 258A
12345